hpv16 e7

HPV16 E7 (86-93) acetate is a derived peptide of human leukocyte antigen A2.1 restricted HPV16 E7 with immunogenic property in cervical carcinomas.

HPV16 E7 (86-93) TFA, a peptide derived from HPV16 E7, is restricted by human leukocyte antigen (HLA)-A2.1 and exhibits immunogenic properties in cervical carcinomas [1] [2].

HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide.

This is amino acids 86 to 93 fragment of the human papilloma virus (HPV) type 16 oncoprotein E7. This HPV16-encoded peptide has very high affinity of binding to the HLA-A*0201 molecule.This immunogenic fragment may be used in vaccines for the prevention a

Acth (7-16)NH2 exhibits neurotrophic effects.

Human Papillomavirus (HPV) E7 protein (49-57) is the H-2d-restricted HPV E749-57 epitope.

Cathepsin D and E FRET Substrate acetate is a fluorogenic substrate selectively cleaved by cathepsins D and E at the Phe-Phe amide bond, demonstrating no activity towards cathepsins B, H, or L. This specificity renders it essential for routine assays and mechanistic studies focusing on cathepsins E and D[1].

HPV16-E711-20 epitope is a well-known HLA-A*0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein, demonstrating high-affinity binding to HLA-A2 in vitro.